Novavax says COVID-19 shot 80% effective in adolescent study
Novavax Inc (NVAX.O) said its two-dose vaccine was 80% effective against COVID-19 in a late-stage trial testing the shot in teens aged 12 to 17 years. The trial involved 2,247 adolescents and took place between May and September last year when the Delta variant was the dominant strain in the United States. The vaccine was 82% …
Novavax says COVID-19 shot 80% effective in adolescent study Read More »